The uremic solute 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) may enhance eryptosis and increase erythrocyte osmotic fragility through potential activation of PIEZO1
Our findings support the hypothesis that CMPF may function as an endogenous activator of PIEZO1, increase icCa2+ levels, trigger eryptosis, and, through this pathway, possibly shorten the RBC lifespan. To what extent these in vitro findings are operative in advanced CKD warrants clinical studies.
Authors
- Erika Sousa Dias (ORCID: https://orcid.org/0000-0002-5743-5772)
- Peter Kotanko (ORCID: https://orcid.org/0000-0003-4373-412X)
- Gabriela Ferreira Dias (ORCID: https://orcid.org/0000-0003-4168-0375)
- Júlia Bacarin Monte Alegre (ORCID: https://orcid.org/0000-0003-2838-3309)
- Beatriz Akemi Kondo Van Spitzenbergen (ORCID: https://orcid.org/0000-0001-7516-9730)
- Nadja Grobe (ORCID: https://orcid.org/0000-0001-9812-7672)
- Andréa Novais Moreno-Amaral (ORCID: https://orcid.org/0000-0002-2730-2952)
- Gabriela Bohnen Andrade
Institutions
- Pontifícia Universidade Católica do Paraná (BR)
- Renal Research Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1093/ndt/gfae275
- Citations
- 3
- Primary Topic
- Erythrocyte Function and Pathophysiology
- Type
- article
- Field-Weighted Citation Impact
- 0.98
Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico